摘要
目的探讨莪术油对卵巢癌裸鼠移植瘤的抑制作用,并探讨其与顺铂联合的协同作用。方法建立卵巢癌细胞株HO-8910PM荷瘤裸鼠模型,随机分为模型对照组、莪术油组、顺铂组和联合给药组(莪术油+顺铂)4组,每组6只,分别腹腔注射莪术油(300 mg·kg-1)、顺铂(2 mg·kg-1)、莪术油联合顺铂(300 mg·kg-1+2 mg·kg-1)以及空白对照液(0.4 mL生理盐水),给药3周后处死小鼠并测瘤体积变化,计算肿瘤生长抑制率,免疫组化检测各组肿瘤组织中NM23、TNF-α、VEGF、NF-KBP65、PCNA的蛋白表达。ELISA检测裸鼠血清中IL-2、IFN-γ水平。结果与模型对照组比较,莪术油、顺铂及其联合给药后均能显著抑制裸鼠肿瘤体积的增长(P<0.05或P<0.01),且联合给药的抑瘤率(55.06%)要高于莪术油(20.5%)和顺铂(52.52%)单独给药。免疫组化检测结果显示各组药物治疗后,能显著降低裸鼠肿瘤组织中NM23、TNF-α、VEGF、NF-KBP65、PCNA的阳性表达(P<0.05或P<0.01),且降低程度从低到高依次为莪术油组、顺铂组、联合给药组。ELISA检测结果也表明顺铂以及莪术油联合顺铂给药3周后能显著提高裸鼠血清IL-2、IFN-γ水平(P<0.01),且含量上升程度由低到高依次为莪术油组、顺铂组、联合给药组。结论莪术油能够抑制卵巢癌荷瘤裸鼠移植瘤的增长,具有一定的抗肿瘤效果,其机制可能与调节肿瘤生长因子NM23、TNF-α、VEGF、NF-KBP65、PCNA及免疫相关因子IL-2、IFN-γ的表达有关。莪术油联合顺铂用药对卵巢癌肿瘤的抑制具有潜在的协同作用,但还需更深入实验研究。
OBJECTIVE To investigate antitumor effect of zedoray turmeric oil(ZTO) on nude mice bearing ovarian cancer and explore its synergistic effect with cisplatin. METHODS After the establishment of HO-8910 PM tumor-bearing mice model, the mice were randomly divided into four groups: model control group(normal saline); ZTO group(300 mg·kg-1);cisplatin group(2 mg·kg-1); combination group(300 mg·kg-1 ZTO+2 mg·kg-1 cisplatin). The nude mice were sacrificed after three weeks of treatment, tumor volume in each group were detected and tumor inhibition rate were calculated. The expression of NM23, TNF-α, VEGF, NF-KBP65, PCNA in tumor tissues were determined by immunohistochemical. ELISA analysis was performed to evaluate the serum level of IL-2 and IFN-γon in nude mice. RESULTS Compared with model group, the tumor volume were significantly decreased in ZTO, cisplatin and combination group(P<0.05 or P<0.01). And the tumor inhibition rates were 20.55%, 52.52%, 55.06%, respectively. Immunohistochemical results showed that the expression of NM23, TNF-α, VEGF,NF-KBP65, PCNA could be significantly decreased with the administration of ZTO, cisplatin, ZTO and cisplatin combined(P<0.05 or P<0.01), and the tendency from low to high were ZTO, cisplatin, ZTO and cisplatin combined in turn. The levels of IL-2 and IFN-γ were also significantly increased with treatment of cisplatin as well as ZTO and cisplatin combined(P<0.01), and the tendency from low to high was the same to above. CONCLUSION ZTO has the anti-tumor effect on ovarian cancer, the underlying mechanism maybe related with regulation of the expression of tumor growth cytokine NM23, TNF-α, VEGF,NF-KBP65, PCNA and immune-related factors IL-2, IFN-γ. And ZTO combined with cisplatin have potential synergistic attenuated the antitumor effect in nude mice of ovarian cancer.
引文
[1]尹定聪,杨华升.莪术油抗肿瘤作用的研究进展[J].中医药导报,2018,34(3):62-63,69.
[2]ZHANG W.Research survey of Chinese native medicine Ezhu[J].J Guangxi Acad Sci(广西科学院学报),2006,22(z1):481-486.
[3]方刚,肖夏清,韩丽娟,等.莪术油抗肿瘤的临床应用及实验研究进展[J].广西中医药大学学报,2009,12(1):61-63.
[4]李国栋,许付,沈爱军.莪术油的研究进展[J].中国药学杂志,2002,37(11):806-809.
[5]DING H Y,TONG Y H,XIN W X,et al.A literature review on economic evaluation of bevacizumab in treatment of ovarian cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2017,34(11):1621-1627.
[6]BRAY F,FERLAY J,JEMAL A,et al.Global cancer statistics2018:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer JClin,2018,68(6):394-424.
[7]LIANG D,YANG M C,LIN Z,et al.The effect of zedoary turmeric oil injection combined with conventional chemotherapy on life quality of the patients with early stage ovarian cancer[J].Chin J Diffic Compl Cas(疑难病杂志),2014,13(5):448-450.
[8]刘竹,韩凤娟,吴效科,等莪术油的抗肿瘤及治疗卵巢癌的研究概况[J].现代中西医结合杂志,2010,19(17):2209-2210.
[9]郭敏红,索玉平,郝美峰,等.莪术油协同卡铂对人卵巢癌耐药细胞株增殖的影响[J].中国药物与临床,2016,16(7):1012-1014.
[10]阮琼芳,钟桂英.莪术油和常规化疗联合治疗卵巢癌的效果分析[J].医学理论与实践,2018,31(4):554-555.
[11]LI Y F,LI M,LIU S J,et al.Effect of zedoary oil on proliferation and platinum resistance of human ovarian cancer SKOV3 cell line[J].Chin Tradit Patent Med(中成药),2013,35(8):1604-1608.
[12]LI R X,LIU S J,KONG D S,et al.Induction of apoptosis and influence on STAT pathway in human cisplatin-resistantovary cancer cell line by zedoary oil[J].Chin Tradit Patent Med(中成药),2013,35(12):2570-2576.
[13]SHI H Q,HU R W,LOU S X,et al.Overexpression of p53and nm23 in patient with ovarian carcinoma[J].Prac Oncol J(实用肿瘤学杂志),2005,19(4):269-271.
[14]BAI Y,XIONG Y J,LIU X G.Expressions and significances of mitofusin-2,Survivin and nm23 in ovarian cancer[J].Mater Child Health Care China(中国妇幼保健),2014,29(13):2079-2081.
[15]CHUFFA A,GUSTAVO L,FERREIRA M,et al.P-MAPAimmunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling[J].JOvarian Res,2018(11):8-18.
[16]古月娟.紫杉醇联合顺铂治疗对卵巢癌患者血清中TNF-α、IL-6和E-cadherin水平的影响[J].卫生职业教育,2017(22):153-155.
[17]CHEN G W,ZHOU Y X,ZHANG J Q,et al.Study of the expression of VEGF,estrogen receptor and progesterone receptor in endometrial adenocarc and its clinicalpathologic feature[J].J Pract Obstetrics Gynecol(实用妇产科杂志),2016,32(2):96-99.
[18]邓志鸿.PCNA在肿瘤病理学上的应用[J].临床与实验病理学杂志,1994(4):331-333.
[19]ANTONY G K,DUDEK A Z.Interleukin 2 in cancer therapy[J].Curr Med Chem,2013,17(29):3297-3302.
[20]AQBI H F,WALLACE M,SAPPAL S,et al.IFN-γorchestrates tumor elimination,tumor dormancy,tumor escape,and progression[J].J Leukocyte Biol,2018(103):1219-1223.